Spatial Concept – Page 3

Rethinking Clinical Trial Data in the Era of Decentralization: Key Trends and Challenges (2025)

4 months ago talkbio0Tagged Artificial Intelligence, Clinical Trials, Data Integration, Data Quality, DCT gene, decentralized, Diversity, Preventive monitoring, regulatory guidance, Remote, risk-based oversight, trials

decentralized clinical trials; DCT; data quality; patient diversity; remote monitoring; AI in trials; data integration; risk-based oversight; clinical trial data; regulatory guidance

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

6 months ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

J&J’s Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear

6 months ago talkbio0Tagged Akeega, Amplitude, Approved, BRCA, HRR gene, Inhibitor, J&J, Malignant neoplasm of prostate, mCSPC, Metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, Mutation, PARP1 gene, United States Food and Drug Administration

Akeega; J&J; prostate cancer; PARP inhibitor; FDA approval; BRCA mutations; HRR gene alterations; AMPLITUDE study; metastatic castration-sensitive prostate cancer (mCSPC); metastatic castration-resistant prostate cancer (mCRPC)

Actuate Therapeutics’ Pancreatic Cancer Drug Elraglusib Shows Survival Benefit in Phase 2 Study

6 months ago talkbio0Tagged 130-nm albumin-bound paclitaxel, Actuate, ASCO, Elraglusib, gemcitabine, Metastatic Pancreatic Ductal Adenocarcinoma, Midline (qualifier value), Pancreatic carcinoma, Survival

Actuate Therapeutics; Elraglusib; Pancreatic cancer; Phase 2 trial; Median overall survival; Gemcitabine; Nab-paclitaxel; Metastatic pancreatic ductal adenocarcinoma; Survival benefit; ASCO 2025

iTeos to Shut Down Operations After TIGIT Therapy Setback

6 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Prime Medicine CEO Exits Amidst Layoffs and Restructuring as Sole Clinical Gene Therapy Shelved

7 months ago talkbio0Tagged CEO, Clinical Trials, Exit, gene therapy, layoffs, pipeline pivot, PM359, Prime Editing, Prime Medicine, restructuring

Prime Medicine; CEO exit; gene therapy; layoffs; restructuring; biotech; PM359; prime editing; clinical trial; pipeline pivot

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

7 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

7 months ago talkbio0Tagged 2025, 75%, 8, Fierce, Generalized, Genomics, NGM, Staff

NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025

Roche could rethink $50B US expansion plan if new policies ‘harm’ operations

7 months ago talkbio0Tagged expansion, Infantile Neuroaxonal Dystrophy, Investments, Policy, Roche (company), United States

Roche (company), United States, Investments, expansion, Policy, Infantile Neuroaxonal Dystrophy

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

7 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes